Kestra Medical Technologies, Ltd. (KMTS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kestra Medical Technologies, Ltd. (KMTS) Healthcare & Pipeline Overview

Kestra Medical Technologies, Ltd. is a Kirkland-based wearable medical device and digital healthcare company specializing in cardiovascular disease. It develops the Cardiac Recovery System platform, featuring the ASSURE WCD for sudden cardiac arrest risk, integrating monitoring, therapeutic treatment, and digital health solutions to enhance patient outcomes and provider engagement.

What Is the Investment Thesis for KMTS?

Kestra Medical Technologies, Ltd. is positioned within the growing wearable medical device market, specifically targeting cardiovascular disease management with its integrated Cardiac Recovery System platform. The company's ASSURE WCD addresses a critical need for patients at high risk of sudden cardiac arrest, offering both therapeutic intervention and continuous monitoring. The integration of digital health solutions within its platform represents a key value driver, enhancing patient engagement and provider oversight, which could lead to improved adherence and outcomes. While the company currently exhibits a negative profit margin of -173.0% and a negative ROE of -92.7%, indicating a growth-stage company investing heavily in market penetration and product development, its gross margin of 48.8% suggests a strong underlying product profitability once scale is achieved. A relatively low Beta of 0.83 indicates lower volatility compared to the broader market. Future growth catalysts are expected from increased adoption of its WCD technology and the expansion of its digital health services, leveraging its $1.40B market capitalization to further innovate and capture market share in the specialized cardiovascular device segment.

Based on FMP financials and quantitative analysis

KMTS Key Highlights

Market capitalization stands at $1.40B, reflecting its valuation in the specialized medical device sector.

• Gross margin of 48.8% indicates strong profitability on products sold, despite overall negative net income.
• Profit margin of -173.0% and Return on Equity (ROE) of -92.7% highlight the company's current investment phase and focus on growth over immediate profitability.
• Debt-to-Equity ratio of 16.16 suggests a reliance on debt financing, which is common for growth-oriented medical technology companies.
• The company's core offering, the ASSURE WCD, integrates monitoring, therapeutic treatment, and digital health, addressing a critical need for patients at risk of sudden cardiac arrest.

Who Are KMTS's Competitors?

KMTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KMTS's Key Strengths?

Integrated Cardiac Recovery System platform offers a comprehensive solution for cardiovascular patient management.

• Proprietary ASSURE WCD addresses a critical medical need for sudden cardiac arrest risk.
• Strong gross margin of 48.8% indicates healthy product-level profitability.
• Focus on digital health integration enhances patient engagement and provider oversight.

What Are KMTS's Weaknesses?

Currently operating with a significant negative profit margin of -173.0% and ROE of -92.7%.

• High debt-to-equity ratio of 16.16 suggests substantial reliance on debt financing.
• Reliance on a specialized market segment (WCDs) could limit immediate broad market reach.
• Potential for high R&D and marketing expenses typical of medical device companies in growth phase.

What Could Drive KMTS Stock Higher?

KMTS catalyst: Regulatory approvals for the Cardiac Recovery System platform in new international markets, opening up new revenue streams and patient populations.

• Continued adoption and increased market penetration of the ASSURE WCD among cardiologists and electrophysiologists due to demonstrated clinical efficacy and patient satisfaction.
• Introduction of enhanced digital health features and services within the Cardiac Recovery System, potentially leading to new subscription-based revenue models.
• Expansion of strategic partnerships with major healthcare systems to integrate Kestra's technology into broader care pathways and improve patient access.

What Are the Key Risks for KMTS?

Negative return on equity (-58.8%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 6 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin of -173.0% and ROE of -92.7% indicate that the company is not yet profitable, posing a risk to sustained operations without further investment.
• Intense competition within the medical device industry, particularly from larger, more established players with greater financial resources and broader product portfolios.
• Regulatory hurdles and compliance costs associated with medical device development and commercialization, which can delay product launches or increase operational expenses.
• Market acceptance and reimbursement challenges for new medical technologies, which could impact the rate of adoption and revenue growth for the Cardiac Recovery System.
• High debt-to-equity ratio of 16.16 could expose the company to financial risks, including interest rate fluctuations or difficulties in securing additional financing.

What Are the Growth Opportunities for KMTS?

• Growth opportunity 1: Expansion of the Wearable Cardioverter Defibrillator (WCD) Market. The global WCD market is projected to grow significantly, driven by an increasing incidence of sudden cardiac arrest (SCA) risk factors and a preference for non-invasive solutions. Kestra's ASSURE WCD is well-positioned to capture a larger share of this expanding market by demonstrating superior patient comfort, compliance, and clinical outcomes. Continued physician education and direct-to-patient outreach can accelerate adoption, particularly in regions with high cardiovascular disease burdens. This market expansion is an ongoing opportunity with long-term potential.
• Growth opportunity 2: Integration and Enhancement of Digital Health Solutions. Kestra's Cardiac Recovery System already includes a suite of integrated digital solutions. Further development and expansion of these digital tools, such as advanced data analytics for predictive insights, AI-driven patient coaching, and seamless electronic health record (EHR) integration, can significantly enhance the platform's value proposition. These enhancements can improve patient adherence, reduce hospital readmissions, and provide more actionable data for clinicians, thereby strengthening Kestra's competitive edge and creating new revenue streams through subscription services. This presents an ongoing opportunity for technological leadership.
• Growth opportunity 3: Geographic Market Expansion. While Kestra is based in Kirkland, US, the global need for advanced cardiovascular monitoring and therapeutic devices is substantial. Pursuing regulatory approvals and establishing distribution channels in new international markets, particularly in Europe and Asia where healthcare infrastructure and demand for advanced medical technologies are growing, represents a significant growth avenue. Strategic partnerships with local healthcare providers or distributors could facilitate faster market entry and penetration, tapping into new patient populations. This is an upcoming opportunity that requires careful planning and execution over the next 3-5 years.
• Growth opportunity 4: Development of New Therapeutic Applications within Cardiovascular Disease. Leveraging its core technology and expertise in wearable monitoring, Kestra could explore expanding its Cardiac Recovery System to address other cardiovascular conditions beyond SCA risk. This could include developing wearable solutions for heart failure management, arrhythmia detection and prevention, or post-cardiac event rehabilitation. Such diversification would broaden the company's addressable market and reduce reliance on a single product line, utilizing its existing technological foundation. This represents a potential long-term growth opportunity, likely within a 5-10 year timeframe.
• Growth opportunity 5: Strategic Partnerships with Healthcare Systems and Payers. Forming deeper collaborations with large hospital systems, integrated delivery networks, and health insurance providers can accelerate the adoption and reimbursement of Kestra's Cardiac Recovery System. These partnerships can facilitate clinical trials, demonstrate cost-effectiveness, and integrate the WCD and digital platform into standard care pathways. Such alliances can also lead to bundled payment models or value-based care agreements, ensuring broader access and sustainable revenue streams for Kestra. This is an ongoing opportunity that can significantly influence market penetration and financial stability.

What Threats Does KMTS Face?

• Intense competition from established medical device manufacturers in the cardiology space.
• Stringent and evolving regulatory landscape for medical devices and digital health solutions.
• Reimbursement challenges and pricing pressures from healthcare payers.
• Rapid technological advancements by competitors could lead to product obsolescence.

What Are KMTS's Competitive Advantages?

• Integrated Cardiac Recovery System platform combining monitoring, therapy, and digital health, offering a comprehensive solution.
• Proprietary wearable cardioverter defibrillator (WCD) technology (ASSURE WCD) addressing a critical unmet medical need.
• Regulatory approvals and clinical evidence for its medical devices, creating barriers to entry for competitors.
• Focus on patient experience and provider engagement through intuitive and connected digital solutions, fostering loyalty and adoption.

What Does KMTS Do?

Kestra Medical Technologies, Ltd., founded in Kirkland, Washington in 2014, operates as a dedicated wearable medical device and digital healthcare company with a core mission to transform patient outcomes in cardiovascular disease. The company achieves this through the development and commercialization of monitoring and therapeutic intervention technologies designed to be intuitive, intelligent, and connected. At the heart of its offerings is the Cardiac Recovery System platform, a comprehensive solution that seamlessly integrates crucial elements such as patient monitoring, therapeutic treatment, advanced digital health capabilities, and robust patient support services. This unified approach aims to provide a holistic care experience for individuals at risk. A flagship component of this platform is the ASSURE Wearable Cardioverter Defibrillator (WCD), a critical device engineered to protect patients who face an elevated risk of sudden cardiac arrest (SCA). Beyond the physical device, Kestra Medical Technologies has also developed an extensive suite of integrated digital solutions and services. These digital tools are designed to foster enhanced engagement between patients and healthcare providers, facilitate improved oversight of patient conditions, and ultimately contribute to superior patient outcomes. The company's focus on integrating cutting-edge wearable technology with sophisticated digital health services positions it within the evolving landscape of connected healthcare, addressing significant unmet needs in cardiovascular disease management.

What Products and Services Does KMTS Offer?

• Develops wearable medical devices for cardiovascular disease management.
• Commercializes the Cardiac Recovery System platform, an integrated solution for patient care.
• Manufactures the ASSURE Wearable Cardioverter Defibrillator (WCD) to protect patients at risk of sudden cardiac arrest (SCA).
• Integrates monitoring, therapeutic treatment, digital health, and patient support services into a unified platform.
• Provides digital solutions and services to enhance patient and provider engagement and oversight.
• Focuses on improving patient outcomes through intuitive, intelligent, and connected technologies.
• Aims to transform care for individuals with cardiovascular conditions.

How Does KMTS Make Money?

• Revenue generation primarily through the sale of its ASSURE WCD devices to healthcare providers and directly to patients.
• Potential for recurring revenue streams from integrated digital health solutions and patient support services, likely through subscription or service fees.
• Focus on a high-value medical device market segment addressing a critical health need (sudden cardiac arrest risk).
• Leveraging technology and innovation to create a comprehensive, integrated solution rather than just a standalone device.

What Industry Does KMTS Operate In?

Kestra Medical Technologies, Ltd. operates within the dynamic Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector characterized by innovation in device technology and digital integration. The market for wearable medical devices, particularly those for cardiovascular monitoring and intervention, is experiencing significant growth driven by an aging population, rising prevalence of chronic diseases, and increasing demand for remote patient monitoring. Kestra's Cardiac Recovery System, centered around the ASSURE WCD, places it directly in the competitive landscape of cardiac rhythm management devices. The industry is marked by stringent regulatory requirements, high R&D costs, and the need for robust clinical evidence. Kestra differentiates itself by offering an integrated platform that combines therapeutic treatment with digital health solutions, aiming to provide a more comprehensive and connected patient experience compared to standalone devices. This positions the company to capitalize on trends towards personalized medicine and value-based care within cardiology.

Who Are KMTS's Key Customers?

• Patients at elevated risk of sudden cardiac arrest (SCA) who require temporary protection.
• Cardiologists and electrophysiologists prescribing WCDs for their patients.
• Hospitals and healthcare systems seeking advanced cardiovascular monitoring and therapeutic solutions.
• Healthcare providers aiming to enhance patient engagement and oversight through digital health tools.

Kestra Medical Technologies, Ltd. (KMTS) Valuation Context

Valued at $1.40B, KMTS is classified as a small-cap stock. Analyst price targets span from $30.00 to $32.00, with a consensus of $31.00. At the current price of $23.92, that implies approximately 30% upside potential. Relative to its peer group, KMTS's quantitative score of 24/100 is below the peer average of 60/100.

KMTS Revenue & Earnings Trend

In Q4 FY2026, KMTS generated $28.6M in top-line revenue, marking a sequential increase of 16.6%. The company recorded a net loss of $38.8M, with diluted EPS of $-0.67. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, KMTS averaged $-0.61 in diluted EPS.

Company Profile

Kestra Medical Technologies, Ltd. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Kirkland, US. The company is led by CEO Brian Webster. KMTS has traded publicly since 2025.

Return on equity for Kestra Medical Technologies, Ltd. stands at -58.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.8%, the inverse of the P/E and a quick read on earnings relative to price.

Kestra Medical Technologies, Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.70 places it in the safe zone, indicating low near-term bankruptcy risk.

Kestra Medical Technologies, Ltd. has missed Wall Street's EPS estimate in 5 of its last 6 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 69.6% below estimates on average.

Over the past six months, Kestra Medical Technologies, Ltd. insiders filed 30 SEC Form 4 transactions — 25 sales and 5 purchases. On net that is roughly 154K shares acquired (about $5.4M) — insiders putting money in tends to read as conviction.

KMTS Financials

KMTS Latest News

KMTS Analyst Consensus

KMTS MoonshotScore

What Investors Ask About Kestra Medical Technologies, Ltd. (KMTS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources